Shots:
- China’s NMPA has approved Sanofi-licensed Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) and Redemplo (plozasiran) for triglyceride reduction in adults with familial chylomicronemia syndrome (FCS) on dietary control
- The approval of Myqorzo was based on the pivotal P-III (SEQUOIA-HCM) study in pts with symptomatic oHCM, while Redemplo’s approval was supported by the pivotal P-III (PALISADE) study in genetically confirmed or clinically diagnosed FCS
- Myqorzo is a selective cardiac myosin inhibitor designed to improve functional capacity and relieve symptoms in oHCM, while Redemplo is an siRNA therapy targeting ApoC-III to address severe hypertriglyceridemia
Ref: Sanofi | Image: Sanofi | Press Release
Related News: Sanofi’s Teizeild (Teplizumab) Receives the EC Approval to Delay Progression of Type 1 Diabetes
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
